Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | KIT | P10721 | 3/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.54 |
| ▸ | MST1R | Q04912 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.51 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | LYN | P07948 | 1/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479181 | 0.92 | KDR (0.59) | KDRKITMETAXLFLT3 | |
| SCHEMBL1479339 | 0.90 | KDR (0.63) | KDRKITMETAXLFLT3 | |
| SCHEMBL2535171 | 0.88 | MET (0.58) | KDRKITMETAXLFLT3 | |
| SCHEMBL2539460 | 0.87 | MET (0.61) | KDRKITMETAXLFLT3 | |
| SCHEMBL2530912 | 0.87 | RET (0.48) | KDRKITMETAXLFLT3 | |
| SCHEMBL2670848 | 0.86 | KDR (0.55) | KDRKITMETAXLFLT3 | |
| SCHEMBL1478499 | 0.84 | KDR (0.54) | KDRKITMETAXLFLT3 | |
| SCHEMBL1478899 | 0.84 | MET (0.76) | KDRKITMETAXLFLT3 | |
| SCHEMBL2542246 | 0.83 | MET (0.57) | KDRKITMETAXLFLT3 | |
| Hydrochloric Acid SCHEMBL1479074 | 0.83 | MET (0.75) | KDRKITMETAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| EP-2332536-A1 | Inhibitors of protein tyrosine kinase activity | MethylGene Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332536-A1 | Inhibitors of protein tyrosine kinase activity | MethylGene Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| WO-2009109035-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | KDR 70/4885KIT 405/4885MET 240/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | KDR 8/4885KIT 468/4885MET 111/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | KDR 8/4885KIT 468/4885MET 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.